National Kidney Registry’s Post

Unused Donor Kidneys Increased Again in 2023 The most recent UNOS/OPTN data clearly emphasizes the critical role 34 Lives will play in rescuing donor kidneys. In 2023, there were 8,574 kidneys recovered with the intent to transplant, but later discarded. This represents 28% of the total (one percent higher, or 1,000 more, than in 2022!). Using OPTN National Data, I created this graph to illustrate the growing scope of the problem with Hard-to-Place kidneys, the focus of our upcoming clinical study. Data such as these motivate us even more to move forward with urgency and commitment. Thanks for your support and commitment, Chris Jaynes, CEO [Reference: transplant.hrsa.gov]

In 2021, there were 786,000 patients living with kidney failure, yet less than 25,000 received a transplant that year. The transplant system is broken and we are determined to fix it. Learn more about how we're fighting for #TransplantsForAll during #DonateLifeMonth and beyond: https://bit.ly/3IZYkCu

As healthcare systems seek opportunities to reduce barriers to care, we are pulling together resources and ideas to share best practices and accelerate efficiency across the Commonwealth. The Virginia Cancer Patient Navigator Network (VACPNN) represents those who strive to eradicate barriers and enhance outcomes for patients, families, and the healthcare team through education, networking, and mutual support. Learn more: https://lnkd.in/gr_EH_xT #VirginiaCancerPlan

We need a shift change in early detection and diagnosis in the Scotland to achieve the ambitious new #LungCancer 42-day waiting time target. Read our report Scottish Pathways Matters on how we can improve outcomes for #LungCancer patients in Scotland 📕▶️ https://ow.ly/jCrf50Q2VUU

In a recent discussion, Richard Finn, MD, and Amit Mahipal, MD, highlighted a new study on #lenvatinib following #immunotherapy for patients with #AdvancedHCC. Learn more: https://buff.ly/3uXjPjI

Consider this: 1 in 4 people are diagnosed with cancer, and 14 million seniors are hospitalized each year. The ability to secure a guaranteed issue between ages 60 and 74 is a no-brainer. Understanding and leveraging these facts can significantly impact your success when selling Hospital Indemnity. Currently, there's a new HIP product on the market 😉 that is an elite offering because of its guaranteed issue feature. I'll let Jordan Fair take it away. Watch the full webinar here >>> https://lnkd.in/gqF6sPCC #HospitalIndemnity #HealthCare #medicare

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices. Watch the interview: https://lnkd.in/eaVw-jdr

Together, we are better. argenx knows well that partnership and collaboration is essential to ensuring a brighter tomorrow for the #raredisease community. This applies in their mission to deliver #immunology treatments to patients across the globe - and especially in their work to develop and deliver a therapy for patients living with Myasthenia Gravis (MG). MG is a rare, neuromuscular disorder where communication between the nerve and the muscle is disrupted, affecting any voluntary muscle movements. Patients living with MG often experience long, complex, and frustrating paths from diagnosis to treatment, but argenx is committed to supporting patients living with MG in their journeys. And that begins with listening. From supporting patient convening sessions, to amplifying patient voices, argenx understands that it’s essential to integrate the patient perspective into every facet of rare disease #drugdevelopment. And we agree. #OneRareVoice #RareDiseaseWeek

My Learning’s in Achieving a Superior Patient Experience: Embracing Long-Term Care: Ensuring Sustainable Patient Outcomes As healthcare providers, our commitment extends beyond the immediate effects of our products or services. Long-term follow-up is not just a choice; it's a necessity. While our businesses may focus on short-term solutions, understanding the enduring impact on patients' quality of life is paramount. It's through long-term evaluation that we can accurately assess the true outcomes of our offerings. We need to prioritize comprehensive care by embracing the importance of sustained monitoring and evaluation in healthcare. CARER - Personalised Cancer Care #PatientOutcomes #Healthcare #IntegrativeOncology

Breast Cancer-Related Lymphedema (BCRL) can be reversed if detected early. Studies from the University of Kansas show that stages 0 and 1 are reversible, while stages 2 and 3 are not. Early intervention and monitoring with Bioimpedance Spectroscopy (BIS) can significantly reduce BCRL rates. Discover how our Lymphedema Prevention Program (LPP) supports early detection and improves patient outcomes. Learn More 🔗https://ow.ly/tonJ50TfBJT. #BCRL #EarlyDetection #LymphedemaPrevention #BreastCancerCare"